Jasper Therapeutics Inc. (JSPR) Reached A New High 2 times During The Past Five Days


As of Friday close, Jasper Therapeutics Inc.’s (NASDAQ:JSPR) stock was up $0.07, moving up 3.89 percent to $1.87. The average number of shares traded per day over the past five days has been 1,587,240 shares. 2 times new highs have been achieved over the past 5 days, with a $0.1400 gain in that time frame. In the last twenty days, the average volume was 1,611,585, while in the previous 50 days, it was 3,228,038.

Since last month, JSPR stock rose 7.16%. Shares of the company fell to $1.5500 on 03/13/23, the lowest level in the past month. A 52-week high of $4.62 was reached on 01/03/23 after having rallying from a 52-week low of $0.39. Since the beginning of this year, JSPR’s stock price has risen by 287.24% or $1.3871, and marked a new high 1 time. However, the stock has declined by -59.52% since its 52-week high.

Do You Know The Best Place To Find Gains In Volatile Markets?

In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.

Click here for full details and to join for free.


JSPR stock investors should be aware that Jasper Therapeutics Inc. (JSPR) stock had its last reported insider trading activity 50 days ago on Jan 27. Carlyle Group Inc., the 10% Owner of the company, purchased of 3,133,333 shares for $1.50 on Jan 27. It resulted in a $4,700,000 investment by the insider. ROCHE HOLDING LTD sold 75,000 shares at an average price of $1.89 on Jan 25. The insider now owns 4,549,606 shares following the transaction. On Jun 27, Director Lis William sold 24,743 shares at $2.08 apiece. The transaction was valued at $51,404.

Financial Health

In the three months ended December 30, Jasper Therapeutics Inc.’s quick ratio stood at 7.10, while its current ratio was 7.10, showing that the company is able to pay off its debt. Based on annual data, JSPR earned $13.51 million in gross profit and brought in $51.2 million in revenue.

JSPR’s revenue rose 100.0% during the quarter, while net income inched up to $0.51 million. While analysts expected Jasper Therapeutics Inc. to report -$0.36 quarterly earnings, the actual figure was -$0.36 per share. The liabilities of Jasper Therapeutics Inc. were 12.37 million at the end of its most recent quarter ended December 30, and its total debt was $3.65 million. The value of shareholders’ equity is $109.38 million.

Technical Picture

This quick technical analysis looks at Jasper Therapeutics Inc.’s (JSPR) price momentum. With a historical volatility rate of 85.92%, the RSI 9-day stood at 50.02% on 17 March.

With respect to its five-day moving average, the current Jasper Therapeutics Inc. price is up by +8.09% percent or $0.1400. At present, JSPR shares trade +2.19% above its 20-day simple moving average and +155.67% percent above its 100-day simple moving average. However, the stock is currently trading approximately -12.62% below its SMA50 and -41.01% below its SMA200.

Stochastic coefficient K was 47.92% and Stochastic coefficient D was 51.39%, while ATR was 0.1740. Given the Stochastic reading of 50.00% for the 14-day period, the RSI (14) reading has been calculated as 51.64%. As of today, the MACD Oscillator reading stands at -0.0344, while the 14-day reading stands at -0.0476.

Analyst Ratings

Cantor Fitzgerald launched its rating on Jasper Therapeutics Inc. (NASDAQ: JSPR) to an Overweight in a note to investors on February 28, 2022. Jasper Therapeutics Inc. (JSPR) has been rated Buy by analysts. According to 0 brokerage firms, JSPR is a sell, and 0 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Jasper Therapeutics Inc. stock as buy, with 5 recommending it as overweight.

With a median target price of $6.43, the current consensus forecast for the stock is $4.00 – $8.00. Based on these forecasts, analysts predict Jasper Therapeutics Inc. (JSPR) will achieve an average price target of $6.21.


Please enter your comment!
Please enter your name here